The U.S. Food and Drug Administration (FDA) has granted fast track designation to ETX-19477, an oral treatment for ovarian cancer currently in early clinical testing.
Gynecological cancer
Gynecological cancer encompasses a group of cancers affecting the female reproductive system. Approximately 100,000 people are diagnosed with gynecological cancer in the U.S. every year. Although each type of gynecological cancer is unique, with its own symptoms, risk factors, and treatment options, reaching an early diagnosis is critical for ensuring the best possible outcomes in any of them.
There are several treatment approaches for gynecological cancer, which encompasses all cancers that originate in the female reproductive system. The choice of treatment will depend on the cancer type, how far it has spread, a patient’s general health status, and other factors, such as whether the patient wishes for their fertility to be preserved.
News
Ernexa Therapeutics is making headway on plans to start clinical testing of ERNA-101, its stem cell therapy designed to treat ovarian cancer. The U.S.
A Phase 1 clinical trial testing the experimental therapy IDE034 in people with various types of cancer, including gynecological cancers, is expected to start…
Dosing has begun in a Phase 3 clinical trial testing Enhertu (trastuzumab deruxtecan) as a maintenance treatment for certain people with ovarian cancer. The…
A new experimental therapy, DT2216, has begun testing in a clinical trial for people with hard-to-treat ovarian cancer, a significant step forward announced by…
The Ovarian Cancer Research Alliance (OCRA) launched a project to push lawmakers to enact legislation that will improve the lives of people affected by…
